Efficacy and safety of aprotinin in cardiac surgery

Orthopedics

Volumn 27, Issue 6 SUPPL., 2004, Pages

  Levy, Jerrold H ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; AMINOCAPROIC ACID; APROTININ; CHYMOTRYPSIN; DESMOPRESSIN; KALLIKREIN; PLASMIN; SERINE PROTEINASE; THROMBIN; TRANEXAMIC ACID; TRYPSIN;

ANAPHYLAXIS; ARTICLE; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CARDIOPULMONARY INSUFFICIENCY; CHILD; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; ENZYME INHIBITION; ERYTHEMA; GRAFT PATENCY; HEART SURGERY; HUMAN; LOW DRUG DOSE; POSTOPERATIVE HEMORRHAGE; SKIN MANIFESTATION; SKIN TEST; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; URINARY EXCRETION;

ANAPHYLAXIS; APROTININ; BLOOD LOSS, SURGICAL; CARDIAC SURGICAL PROCEDURES; HEMOSTATICS; HUMANS; KIDNEY;

EID: 3142754386     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Levy JH. Anaphylactic Reactions in Anesthesia and Intensive Care. 2nd ed. Stoneham, Mass: Butterworth-Heinemann; 1992.
2. Peters DC, Noble S. Aprotinin: an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery. Drugs. 1999; 57:233-260.
3. Cosgrove DM, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg. 1992; 4:1031-1038.
4. Levy JH, Pifarre R, Schaff H, et al. A multicenter, placebo-controlled, double-blind trial of aprotinin for repeat coronary artery bypass grafting. Circulation. 1995; 92: 2236-2244.
5. Alderman EL, Levy JH, Rich J, et al. International multi-center aprotinin graft patency experience (IMAGE). J Thorac Cardiovasc Surg. 1998; 116:716-730.
6. Bidstrup BP, Underwood SR, Sapsford RN, Streets EM. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg. 1993; 105:147-153.
7. Havel M, Grabenwoger F, Schneider J. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg. 1994; 107:807-810.
8. Lemmer JH, Jr, Dilling EW, Mortin JR, et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial for three dose regimens. Ann Thorac Surg. 1996; 62:1659-1667.
9. Miller BE, Tosone SR, Tam VKH, et al. Hematologic and economic impact of aprotinin in reop pediatric cardiac surgery. Ann Thorac Surg. 1998; 66:535-540.
10. Munoz JJ, Birkmeyer NJ, Birkmeyer JD, et al. Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery?: a meta-analysis. Circulation. 1999; 99:81-89.
11. Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant end-points. Lancet. 1999; 354:1940-1947.
12. Dietrich W, Barankay A, Dilthey G, et al. Reduction of homologous blood requirement in cardiac surgery by intraoperative aprotinin application: clinical experience in 152 cardiac surgical patients. Thorac Cardiovasc Surg. 1989; 37:92-98.
13. Dietrich W, Spaeth P, Ebell A, Richter JA. Incidence of anaphylactic reactions to aprotinin: analysis of 248 reexposures to aprotinin. J Thorac Cardiovasc Surg. 1997; 113:194-201.
14. Jaquis DB, Ghanayem NS, Zacharisen MC, Mussatto KA, Tweddell JS, Litwin SB. Safety of aprotinin use and re-use in pediatric cardiothoracic surgery. Circulation. 2002; 106:90-94.
15. Scheule AM, Beierlein W, Arnold S, Eckstein FS, Albes JM, Ziemer G. The significance of preformed aprotinin-specific antibodies in cardiosurgical patients. Anesth Analg. 2000; 90:262-266.
16. Levy JH, Bailey JM, Salmenpera M. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. Anesthesiology. 1994; 80:1013-1018.
17. Levy JH, Murkin J, Ramsay JG. Aprotinin reduces the incidence of strokes following cardiac surgery. Circulation. 1996; 94:1-535.
18. Feindt PR, Walcher S, Volkmer I. Effects of high-dose aprotinin on renal function in aortocoronary bypass grafting. Ann Thorac Surg. 1995; 60:1076-1080.
19. D'Ambra MN, Akins CW, Blackstone EH, et al. Aprotinin in primary valve replacement and reconstruction: a multicenter double-blind placebo-controlled trial. J Thorac Cardiovasc Surg. 1996; 112:1081-1089.
20. Lemmer JH, Stanford W, Bonney SL. Aprotinin for coronary artery bypass grafting: effect on postoperative renal function. Ann Thorac Surg. 1995; 59:132-136.
21. Lemmer JH, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass surgery: efficacy, safety, and influence on early saphenous vein graft patency. J Thorac Cardiovasc Surg. 1994; 107:543-553.
22. Lemmer JH, Stanford W, Bonney SL, et al. Aprotinin for coronary artery bypass grafting: effect on postoperative renal function. Ann Thorac Surg. 1995; 59:132-136.
23. Swart MJ, Gordon PC, Hayse-Gregson PB, et al. High-dose aprotinin in cardiac surgery: a prospective, randomized study. Anaesth Intensive Care. 1994; 22:529-533.